Found: 315
Select item for more details and to access through your institution.
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1434, doi. 10.1002/ajh.27333
- By:
- Publication type:
- Article
Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 5, p. 1513, doi. 10.1007/s00277-023-05426-9
- By:
- Publication type:
- Article
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
- Published in:
- EJHaem, 2024, v. 5, n. 1, p. 105, doi. 10.1002/jha2.854
- By:
- Publication type:
- Article
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
- Published in:
- Acta Haematologica, 2023, v. 146, n. 6, p. 522, doi. 10.1159/000533875
- By:
- Publication type:
- Article
Impact of Red Blood Cell Transfusions on Quality of Life for Patients With Myelofibrosis in the SIMPLIFY-1 and SIMPLIFY-2 Clinical Trials.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2023, v. 14, n. 11, p. 357
- By:
- Publication type:
- Article
Reappraisal of Cardiovascular Risk Factors in Patients With Chronic Myeloproliferative Neoplasms.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 10, p. 541
- By:
- Publication type:
- Article
The role of therapy in the outcome of patients with myelofibrosis.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 18, p. 2828, doi. 10.1002/cncr.34851
- By:
- Publication type:
- Article
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01471-z
- By:
- Publication type:
- Article
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project.
- Published in:
- Biomedicines, 2023, v. 11, n. 7, p. 1925, doi. 10.3390/biomedicines11071925
- By:
- Publication type:
- Article
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.
- Published in:
- Cancers, 2023, v. 15, n. 13, p. 3331, doi. 10.3390/cancers15133331
- By:
- Publication type:
- Article
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 11, p. 1681, doi. 10.1002/cncr.34707
- By:
- Publication type:
- Article
How I manage anemia related to myelofibrosis and its treatment regimens.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 4, p. 689, doi. 10.1007/s00277-023-05126-4
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 4, p. 219, doi. 10.1016/j.clml.2022.12.014
- By:
- Publication type:
- Article
Real-world treatments and thrombotic events in polycythemia vera patients in the USA.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 3, p. 571, doi. 10.1007/s00277-023-05089-6
- By:
- Publication type:
- Article
A Review of Essential Thrombocythemia and Its Complications.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 2, p. 76
- By:
- Publication type:
- Article
Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.
- Published in:
- EJHaem, 2022, v. 3, n. 4, p. 1346, doi. 10.1002/jha2.591
- By:
- Publication type:
- Article
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 377
- By:
- Publication type:
- Article
Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) (MOMENTUM).
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 388
- By:
- Publication type:
- Article
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.
- Published in:
- Current Hematologic Malignancy Reports, 2022, v. 17, n. 5, p. 155, doi. 10.1007/s11899-022-00670-8
- By:
- Publication type:
- Article
Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 4, p. 491, doi. 10.1002/hon.2987
- By:
- Publication type:
- Article
Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)‐I study.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 6, p. 1065, doi. 10.1111/bjh.18329
- By:
- Publication type:
- Article
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 8, p. 1885, doi. 10.1007/s00277-022-04839-2
- By:
- Publication type:
- Article
Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 3, p. 604, doi. 10.1111/bjh.18278
- By:
- Publication type:
- Article
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 317, doi. 10.1111/bjh.18207
- By:
- Publication type:
- Article
The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 14, p. 2717, doi. 10.1002/cncr.34222
- By:
- Publication type:
- Article
Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.
- Published in:
- Cancers, 2022, v. 14, n. 14, p. N.PAG, doi. 10.3390/cancers14143474
- By:
- Publication type:
- Article
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
- Published in:
- Acta Haematologica, 2022, v. 145, n. 4, p. 448, doi. 10.1159/000520440
- By:
- Publication type:
- Article
Defining disease modification in myelofibrosis in the era of targeted therapy.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 13, p. 2420, doi. 10.1002/cncr.34205
- By:
- Publication type:
- Article
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e1, doi. 10.1016/j.clml.2022.02.001
- By:
- Publication type:
- Article
Cases in the Management of Polycythemia Vera: Switching From Hydroxyurea to Ruxolitinib to Resolve Symptoms and Improve Quality of Life.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 8, p. 2
- By:
- Publication type:
- Article
Higher red blood cell distribution width predicts thrombosis risk in primary and secondary myelofibrosis.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 5, p. 305, doi. 10.1016/j.clml.2021.10.012
- By:
- Publication type:
- Article
Improved survival of patients with myelofibrosis in the last decade: Single‐center experience.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 8, p. 1658, doi. 10.1002/cncr.34103
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 210, doi. 10.1016/j.clml.2021.10.002
- By:
- Publication type:
- Article
Erratum to 'Potential New Therapeutic Approaches for Myelofibrosis' [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S130-S133/EXABS-189-MPN].
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 277, doi. 10.1016/j.clml.2021.12.001
- By:
- Publication type:
- Article
Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-08606-1
- By:
- Publication type:
- Article
Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-021-01157-4
- By:
- Publication type:
- Article
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 1, p. 131, doi. 10.1007/s00277-021-04682-x
- By:
- Publication type:
- Article
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 9 /L to <100 × 10 9 /L) at baseline: the final analysis of EXPAND.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221118429
- By:
- Publication type:
- Article
Phase II study of single-agent nivolumab in patients with myelofibrosis.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 12, p. 2957, doi. 10.1007/s00277-021-04618-5
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 10, p. 641, doi. 10.1016/j.clml.2021.06.008
- By:
- Publication type:
- Article
Potential New Therapeutic Approaches for Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S130, doi. 10.1016/S2152-2650(21)01238-6
- By:
- Publication type:
- Article
Poster: CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S222, doi. 10.1016/S2152-2650(21)01401-4
- By:
- Publication type:
- Article
Poster: MPN-164: Overall Survival (OS) and Progression-Free Survival (PFS) in Patients Treated with Fedratinib as First-Line Myelofibrosis (MF) Therapy and after Prior Ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 Trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01454-3
- By:
- Publication type:
- Article
Poster: MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01453-1
- By:
- Publication type:
- Article
Poster: MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01456-7
- By:
- Publication type:
- Article
Poster: MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01455-5
- By:
- Publication type:
- Article
Poster: MPN-314: Improved Survival of Patients with Primary Myelofibrosis in the Last Decade at a Large Single Academic Center.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S232, doi. 10.1016/S2152-2650(21)01458-0
- By:
- Publication type:
- Article
Poster: MPN-383: GLI1 Promotes the Pro-Fibrotic Function of Monocyte-Derived Fibrocytes in Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S232, doi. 10.1016/S2152-2650(21)01461-0
- By:
- Publication type:
- Article